In a nutshell Researchers identified two distinct brain pathways that determine whether an odor feels pleasant or threatening, shedding light on how our brains emotionally interpret smells. These same ...

Everyone has a different baseline, influenced by genetic factors such as our DRD2 dopamine receptor genes. Some people produce and metabolise dopamine faster than other people.

June 11, 2025 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage biopharmaceutical company ...

Furthermore, through transfer learning, the model generates molecules specifically targeting the DRD2 protein, with the newly designed molecules exhibiting pharmacological properties similar to known ...

Hippocampal sharp wave-ripples during sleep are enhanced by food intake in a calorie-dependent manner and are associated with increased activity of lateral hypothalamic GABAergic neurons.

The ER membrane protein SELENOT has been previously suggested to be neuroprotective, but its contribution to neuronal pathophysiology has not been thoroughly investigated. This study reports that ...

Chimerix’s lead clinical pipeline candidate is dordaviprone, a first-in-class small molecule treatment designed to selectively target the mitochondrial protease ClpP and dopamine receptor D2 (DRD2).

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in depression in those of European and non-European ancestry.

Carotid endarterectomy (CEA) is widely used to treat carotid artery stenosis (CAS). However, the effects of CEA on unilateral CAS‐induced cognitive impairment and the underlying mechanism remain ...

Variants of the DRD2 gene – which plays a key role in dopamine signaling in relation to attention, motivation, impulsivity control and reward processing – are attributed to the poor dopamine ...

Chimerix submitted a new drug application to the FDA seeking accelerated approval for dordaviprone to treat patients with recurrent H3 K27M-mutant diffuse glioma.